Published in J Clin Oncol on September 01, 1988
Screening for psychiatric morbidity in patients with advanced breast cancer: validation of two self-report questionnaires. Br J Cancer (1991) 1.83
Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer (1997) 1.81
Systemic adjuvant therapy for node-negative breast cancer. CMAJ (1989) 1.42
Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer (2003) 1.14
Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer. Br J Cancer (2000) 1.07
A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer. Br J Cancer (1991) 1.02
Do patients with advanced breast cancer benefit from chemotherapy? Br J Cancer (1998) 1.01
Systemic therapy of advanced breast cancer. Drugs (1992) 0.99
Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers? Br J Cancer (1993) 0.92
A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer. Br J Cancer (1991) 0.87
Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer. Br J Cancer (1994) 0.85
Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer. Br J Cancer (1998) 0.84
Breast cancer (metastatic). BMJ Clin Evid (2007) 0.82
A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-cell lung cancer: a Cancer research Campaign trial. Br J Cancer (1996) 0.81
Dose intensity in cancer chemotherapy. Br J Cancer (1990) 0.81
Cancer therapy: reimbursement of new therapeutic technologies. Yale J Biol Med (1992) 0.78
Dose intensity as a therapeutic strategy in breast cancer. Breast Cancer Res Treat (1991) 0.77
Breast cancer (metastatic). BMJ Clin Evid (2010) 0.77
Willingness to pay to avoid metastatic breast cancer treatment side effects: results from a conjoint analysis. Springerplus (2014) 0.77
A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer. Br J Cancer (1993) 0.77
Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast. Br J Cancer (1999) 0.77
Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment. Eur J Clin Pharmacol (2016) 0.75
Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. Clin Breast Cancer (2010) 0.75
Prognostic factors related to response to chemotherapy in metastatic breast cancer. J Clin Oncol (1989) 0.75
High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study. Br J Cancer (1998) 0.75
The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer. Br J Cancer (1995) 0.75
Dose-intensive treatment of breast cancer supported by granulocyte-macrophage colony-stimulating factor (GM-CSF). Breast Cancer Res Treat (1991) 0.75
The quantitative analysis of mammographic densities. Phys Med Biol (1994) 5.71
Patients' willingness to enter clinical trials: measuring the association with perceived benefit and preference for decision participation. Soc Sci Med (1991) 2.77
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol (1998) 2.51
Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol (1996) 2.35
Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev (2001) 2.35
P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med (1991) 2.32
Case-control study of factors associated with failure to detect breast cancer by mammography. J Natl Cancer Inst (1992) 2.31
Localization of a putative transcriptional regulator (ATRX) at pericentromeric heterochromatin and the short arms of acrocentric chromosomes. Proc Natl Acad Sci U S A (1999) 2.24
The development of a method for assessing the quality of life of cancer patients. Br J Cancer (1984) 2.23
A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol (1988) 2.14
The review of randomization in the Canadian National Breast Screening Study. Is the debate over? CMAJ (1997) 2.07
The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol (2003) 2.03
Symmetry of projection in the quantitative analysis of mammographic images. Eur J Cancer Prev (1996) 2.00
Mammographic parenchymal patterns: a marker of breast cancer risk. Epidemiol Rev (1993) 1.97
Optical second harmonic generation in biological systems. Appl Opt (1971) 1.89
Mammographic density, lobular involution, and risk of breast cancer. Br J Cancer (2008) 1.83
Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med (1982) 1.79
Emotion knowledge as a predictor of social behavior and academic competence in children at risk. Psychol Sci (2001) 1.77
Analysis of mammographic density and breast cancer risk from digitized mammograms. Radiographics (1999) 1.77
Second primary malignancies following diagnosis of small-cell lung cancer. J Clin Oncol (1992) 1.77
Automated analysis of mammographic densities. Phys Med Biol (1996) 1.74
Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res (1998) 1.70
The risk of breast cancer associated with mammographic parenchymal patterns: a meta-analysis of the published literature to examine the effect of method of classification. Cancer Detect Prev (1992) 1.67
Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res (1996) 1.57
Ontario familial colon cancer registry: methods and first-year response rates. Chronic Dis Can (2000) 1.55
Critical appraisal of the evidence that dietary fat intake is related to breast cancer risk in humans. J Natl Cancer Inst (1987) 1.52
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia (2005) 1.51
Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung. J Clin Oncol (1984) 1.51
Body size and breast cancer prognosis: a critical review of the evidence. Breast Cancer Res Treat (1990) 1.50
The measurement of patients' values in medicine. Med Decis Making (1982) 1.44
Body weight and prognosis in breast cancer. J Natl Cancer Inst (1981) 1.44
Quantitative correlation of breast tissue parameters using magnetic resonance and X-ray mammography. Br J Cancer (1996) 1.43
Fish consumption and breast cancer risk: an ecological study. Nutr Cancer (1989) 1.38
Necrosis in a meningioma following systemic chemotherapy. Case report. J Neurosurg (1994) 1.38
Automated analysis of mammographic densities and breast carcinoma risk. Cancer (1997) 1.38
Neuronal fractalkine expression in HIV-1 encephalitis: roles for macrophage recruitment and neuroprotection in the central nervous system. J Immunol (2000) 1.38
Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther (2005) 1.36
Scientific problems in clinical scales, as demonstrated in the Karnofsky index of performance status. J Chronic Dis (1979) 1.34
Reducing child poverty in Britain: an assessment of government policy, 1997-2001. Econ J (London) (2001) 1.33
Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res (2000) 1.32
Variegated expression of a globin transgene correlates with chromatin accessibility but not methylation status. Nucleic Acids Res (1996) 1.29
The frequency of malignant neoplasms in patients with polymyositis-dermatomyositis. A controlled study. Arch Intern Med (1985) 1.28
Mammographic signs as risk factors for breast cancer. Br J Cancer (1982) 1.28
Molecular markers in male breast carcinoma. Cancer (1998) 1.26
Agreement between parent and child report of quality of life in children with attention-deficit/hyperactivity disorder. Child Care Health Dev (2006) 1.26
Breast cancer risk and measured mammographic density. Eur J Cancer Prev (1998) 1.26
Macronutrient intake and change in mammographic density at menopause: results from a randomized trial. Cancer Epidemiol Biomarkers Prev (1999) 1.24
Eliciting preferences for alternative cancer drug treatments. The influence of framing, medium, and rater variables. Med Decis Making (1985) 1.24
Respiratory exposures associated with silicon carbide production: estimation of cumulative exposures for an epidemiological study. Br J Ind Med (1984) 1.23
Ratings of the importance of quality of life variables: therapeutic implications for patients with metastatic breast cancer. J Clin Epidemiol (1990) 1.23
Eliciting preferences for alternative drug therapies in oncology: influence of treatment outcome description, elicitation technique and treatment experience on preferences. J Chronic Dis (1987) 1.21
Weight gain in women with localized breast cancer--a descriptive study. Breast Cancer Res Treat (1988) 1.20
Corneal injury threshold to carbon dioxide laser irradiation. Am J Ophthalmol (1968) 1.20
Mammographic parenchymal pattern and breast cancer risk: a critical appraisal of the evidence. Am J Epidemiol (1988) 1.19
A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. J Clin Oncol (1987) 1.19
Ocular involvement in neuroblastoma: prognostic implications. Ophthalmology (1984) 1.16
Comparison of energy intakes determined by food records and doubly labeled water in women participating in a dietary-intervention trial. Am J Clin Nutr (1996) 1.15
Neurologic disorders in patients with small cell lung cancer. Cancer (1987) 1.15
MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res (1997) 1.14
Describing health states. Methodologic issues in obtaining values for health states. Med Care (1984) 1.13
Weight gain during adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat (1985) 1.11
Fast-to-slow transformation in stimulated rat muscle. Muscle Nerve (1996) 1.09
Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer. J Clin Oncol (1985) 1.08
Clinicopathologic correlation of the multiple recurrent serosanguineous retinal pigment epithelial detachments syndrome. Retina (1994) 1.08
Adiposity changes after a 1-year aerobic exercise intervention among postmenopausal women: a randomized controlled trial. Int J Obes (Lond) (2010) 1.07
The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer. J Clin Oncol (1991) 1.06
Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant (2003) 1.04
Attitudes toward quality of survival. The concept of "maximal endurable time". Med Decis Making (1982) 1.04
Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. CMAJ (1993) 1.03
Atypical hyperplasia and breast cancer risk: a critique. Cancer Causes Control (1992) 1.03
The detection of change in mammographic density. Cancer Epidemiol Biomarkers Prev (2003) 1.03
Cytotoxicity of adriamycin in MGH-U1 cells grown as monolayer cultures, spheroids, and xenografts in immune-deprived mice. Cancer Res (1984) 1.03
Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. Cancer Res (1999) 1.02
Observer variation in the classification of mammographic parenchymal patterns. J Chronic Dis (1986) 1.01
Ochronosis in a murine model of alkaptonuria is synonymous to that in the human condition. Osteoarthritis Cartilage (2012) 1.00
Superior vena caval obstruction syndrome in small cell lung cancer. Cancer (1986) 1.00
Quantitative evaluation of mammographic densities: a comparison of methods of assessment. Eur J Cancer Prev (1995) 1.00
Male breast cancer: a 13-year review of 89 patients. J Clin Oncol (1984) 1.00
Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. J Clin Oncol (2000) 1.00
Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res (2001) 1.00
Importance of clinical staging in limited small-cell lung cancer: a valuable system to separate prognostic subgroups. The University of Toronto Lung Oncology Group. J Clin Oncol (1993) 1.00
Temporal trends in breast cancer surgery in Ontario: can one randomized trial make a difference? CMAJ (1994) 1.00
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Clin Cancer Res (2000) 1.00
A randomized trial of the total design method for the postal follow-up of women in a cancer prevention trial. Eur J Cancer Prev (1996) 0.99
Adjuvant therapy for stage III colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group. Cancer Prev Control (1997) 0.98
A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia (2007) 0.98
A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res (2000) 0.98
Childhood and adolescent depression: child-report versus parent-report information. J Am Acad Child Psychiatry (1985) 0.97
Is bone marrow examination in small-cell lung cancer really necessary? Ann Intern Med (1986) 0.97
Intracoronary delivery of adenovirus encoding adenylyl cyclase VI increases left ventricular function and cAMP-generating capacity. Circulation (2000) 0.97
Combined modality treatment with radiotherapy and chemotherapy. Radiother Oncol (1989) 0.95
P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst (1997) 0.94
Quantitative magnetic resonance imaging parameters and their relationship to mammographic pattern. J Natl Cancer Inst (1992) 0.94
Carcinoembryonic antigen: a useful prognostic marker in small-cell lung cancer. J Clin Oncol (1985) 0.94
Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol (1998) 0.93